MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today the presentation of data at the 55th Annual Meeting of the Radiation Research Society detailing the effectiveness of AEOL 10150 as a countermeasure to radiation exposure in the lungs in mice. Data presented were from a study led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University Medical Center, and showed that the compound demonstrated statistically significant increase in survival, protection against radiation induced body weight loss; normalization of wet lung weight increase and reduction of radiation-induced inflammation by removing free radicals and regulating HIF-1a signaling.
